Christine Silverstein Biography and Net Worth

Director of Abeona Therapeutics

Christine Silverstein brings over 15 years of experience in corporate finance and capital markets strategy. Christine serves as Chief Financial Officer at Excision Biotherapeutics, a CRISPR gene-editing company for viral infectious dieseases. Prior to her current role, she was the Chief Financial Officer of Emendo Biotherapeutics, a gene editing company (acquired by Anges Inc, a gene-based medicines company in December 2020). Silverstein formerly served as Chief Financial Officer and Principal Financial Offer for Abeona. She has held various executive roles within the biotechnology industry including Head of Investor Relations at Relmada Therapeutics, Inc., Vice President of Corporate Development at PlasmaTech Biopharmaceuticals, and Managing Director at SCO Financial Group, a life sciences fund. Earlier in her career, she held senior positions at leading New York corporate and capital market advisory firms. Silverstein began her career in financial services as an investment advisor at Royal Alliance Associates. A member of the National Investor Relations Institute, Ms. Silverstein holds a B.S. from the Peter Tobin College of Business at St. John's University and has earned various accreditations from the Financial Industry Regulatory Agency.

What is Christine Berni Silverstein's net worth?: The estimated net worth of Christine Berni Silverstein is at least $586.73 thousand as of July 9th, 2025. Mr. Silverstein owns 120,479 shares of Abeona Therapeutics stock worth more than $586,733 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Silverstein may own. Learn More about Christine Berni Silverstein's net worth.
How do I contact Christine Berni Silverstein?: The corporate mailing address for Mr. Silverstein and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Christine Berni Silverstein's contact information.
Has Christine Berni Silverstein been buying or selling shares of Abeona Therapeutics?: Christine Berni Silverstein has not been actively trading shares of Abeona Therapeutics in the last ninety days. Most recently, Christine Berni Silverstein sold 13,093 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a transaction totalling $76,724.98. Following the completion of the sale, the director now directly owns 120,479 shares of the company's stock, valued at $706,006.94. Learn More on Christine Berni Silverstein's trading history.
Who are Abeona Therapeutics' active insiders?: Abeona Therapeutics' insider roster includes Leila Alland (Director), Mark Alvino (Director), Michael Amoroso (CEO), Edward Carr (CAO), Faith Charles (Director), Brendan O'Malley (SVP), Vishwas Seshadri (CEO), Christine Silverstein (Director), Joseph Vazzano (CFO), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.
Are insiders buying or selling shares of Abeona Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 351,238 shares worth more than $2,047,717.92. The most recent insider tranaction occured on November, 13th when Director Mark Alvino sold 15,000 shares worth more than $71,100.00. Insiders at Abeona Therapeutics own 6.9% of the company. Learn More about insider trades at Abeona Therapeutics.
Information on this page was last updated on 11/13/2025.

Christine Berni Silverstein Insider Trading History at Abeona Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/9/2025	Sell	13,093	$5.86	$76,724.98	120,479
9/27/2023	Sell	6,330	$3.91	$24,750.30	87,884

Christine Berni Silverstein Buying and Selling Activity at Abeona Therapeutics

Abeona Therapeutics Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Today's Range

Now: $4.87

$4.69

$4.92

50 Day Range

MA: $4.99

$4.17

$5.66

2 Week Range

Now: $4.87

$3.93

$7.54

Volume

954,439 shs

Average Volume

2,466,979 shs

Market Capitalization

$263.91 million

P/E Ratio

3.96

Dividend Yield

N/A

Beta

1.12